Twist Bioscience : JP Morgan 2023 FINAL

J A N U A R Y 2 0 2 3

WRITING THE FUTURE

Legal Disclaimers

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, financial guidance for fiscal 2023 and 2024 and the first quarter of fiscal 2023, statements regarding future growth, expansion, market share gains, plans to achieve adjusted EBITDA break-even for Twist's core business and biopharma and Twist Bioscience's other expectations regarding its future operations plans and financial performance, expected commencement of product shipment from the "Factory of the Future" in January 2023; timing of the early access launch of Twist Bioscience's first DNA data storage solution, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies, including Abveris, and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 28, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

2 T w i s t B i o s c i e n c e

W R I T I N G T H E F U T U R E O N E D N A S T R A N D AT A T I M E

							C e l l t h e r a p y		D a t a s t o r a g e
				E n z y m e e n g i n e e r i n g	P r o t e i n e n g i n e e r i n g
		S t r u c t u r a l g e n o m i c s	M i n i m a l r e s i d u a l d i s e a s e	A g r i g e n o m i c s
	G e n e a l o g y	L i q u i d b i o p s y		G l o b a l f o o d s e c u r i t y		C a r b o n r e c y c l i n g
	H e r e d i t a r y t e s t i n g	C a n c e r t e s t i n g		G e n e t h e r a p y		P e r s o n a l i z e d m e d i c i n e
P o p u l a t i o n g e n e t i c s	F o r e n s i c s	A n t i b o d y t h e r a p e u t i c s	V a c c i n e d e v e l o p m e n t
G e n e t i c s c r e e n i n g	R a r e d i s e a s e t e s t i n g		N u t r i t i o n			A n i m a l h e a l t h
G l o b a l f o o d s e c u r i t y		P a t h o g e n s u r v e i l l a n c e	P r o t e i n d e g r a d a t i o n
A n c i e n t D N A	N e u r o s c i e n c e	T a r g e t D i s c o v e r y		I n f e c t i o u s d i s e a s e		M i c r o b i o l o g y
M a t e r i a l s c i e n c e	T r a n s l a t i o n a l r e s e a r c h			I n d u s t r i a l c h e m i c a l i n g r e d i e n t s

D N A . R N A . P R O T E I N S .

3 T w i s t B i o s c i e n c e

For Research Use Only. Not for use in diagnostic procedures

Twist is:

I N N O VAT I O N

COMMERCIAL EXECUTION

PATH TO PROFITABILITY

4 T w i s t B i o s c i e n c e

Twist DNA Writing on Silicon Platform

Everyone Else

1 oligo per well

1M oligos per chip

		Up to
		10,000X
96 Well Plate	Twist Silicon Platform	more scale
& throughput
makes 1 gene	can make 9,600 genes

5 T w i s t B i o s c i e n c e

State of the art

commercial

infrastructure

Proprietary SW powering:

Integrated

eCommerce platform Custom instruments

Manufacturing execution system